ArticleGastro hep advances2026
Outcome-Specific Cardiovascular and Hypertensive Risk Profiles in Metabolic Dysfunction-Associated Steatotic Liver Disease: Insights From a Competing Risk Cohort Analysis.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early Cardiotoxic Remodelling Precedes Hepatic Fibrosis and Increases Susceptibility to Lethal Arrhythmias in Wild-Type MASH Mice.Clinical and experimental pharmacology & physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a cardiovascular risk factor affecting one in four adults globally. However, it remains unclear whether MASLD uniformly elevates risk across cardiometabolic outcomes. We investigated the outcome-specific associations of MASLD, incident cardiovascular disease (CVD), and hypertension (HTN) in a large Asian cohort. Methods: We analyzed 24,384 adults (median age 51.4 years; 51.2% women) enrolled in a retrospective Japanese health-screening program (2007-2022). MASLD was diagnosed based on the criteria of ultrasonography-confirmed hepatic steatosis and metabolic dysfunction. Primary outcomes were major adverse cardiovascular events and new-onset arterial HTN. We applied time-dependent Cox regression, multistate modeling, and Fine-Gray competing risk analysis over 127,419 person-years (median follow-up: 5.2 years). Results: Baseline MASLD prevalence was 23.8%. MASLD significantly increased the risk of CVD (adjusted hazard ratio: 1.83; 95% confidence interval: 1.63-2.07; Conclusion: MASLD substantially increased cardiovascular risk but showed minimal association with HTN. These findings challenge the assumption of a uniform cardiometabolic risk in MASLD and underscore the need for outcome-specific risk stratification and targeted CVD prevention in patients with MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.